User login
Key clinical point: The alpha-calcitonin gene-related peptide (CGRP) level was significantly elevated in patients with chronic migraine (CM) vs control individuals, which eventually normalized after treatment with CGRP monoclonal antibodies (mAb) and correlated with clinical response.
Major finding: The significantly higher alpha-CGRP levels in patients with CM vs control individuals (P = .004) normalized at 2 weeks (median 40.4 pg/mL; 95% CI 35.6-48.1 pg/mL) and 3 months (median 40.9 pg/mL; 95% CI 36.3-45.9 pg/mL) post-treatment with a CGRP mAb. A significant correlation was observed between decrease in monthly migraine days at the third month and absolute decrease in alpha-CGRP content at the same time-point (P = .02).
Study details: The data come from an observational study including 103 patients with CM who initiated treatment with CGRP mAb and 78 matched control individuals.
Disclosures: This study was supported by the Instituto de Salud Carlos III, IDIVAL Spain, and Lilly grant. J Pascual and V González-Quintanilla declared receiving advisory or speaker honoraria from various sources, including Lilly. Other authors declared no conflicts of interest.
Source: Gárate G et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023 (Apr 11). doi: 10.1002/ana.26658
Key clinical point: The alpha-calcitonin gene-related peptide (CGRP) level was significantly elevated in patients with chronic migraine (CM) vs control individuals, which eventually normalized after treatment with CGRP monoclonal antibodies (mAb) and correlated with clinical response.
Major finding: The significantly higher alpha-CGRP levels in patients with CM vs control individuals (P = .004) normalized at 2 weeks (median 40.4 pg/mL; 95% CI 35.6-48.1 pg/mL) and 3 months (median 40.9 pg/mL; 95% CI 36.3-45.9 pg/mL) post-treatment with a CGRP mAb. A significant correlation was observed between decrease in monthly migraine days at the third month and absolute decrease in alpha-CGRP content at the same time-point (P = .02).
Study details: The data come from an observational study including 103 patients with CM who initiated treatment with CGRP mAb and 78 matched control individuals.
Disclosures: This study was supported by the Instituto de Salud Carlos III, IDIVAL Spain, and Lilly grant. J Pascual and V González-Quintanilla declared receiving advisory or speaker honoraria from various sources, including Lilly. Other authors declared no conflicts of interest.
Source: Gárate G et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023 (Apr 11). doi: 10.1002/ana.26658
Key clinical point: The alpha-calcitonin gene-related peptide (CGRP) level was significantly elevated in patients with chronic migraine (CM) vs control individuals, which eventually normalized after treatment with CGRP monoclonal antibodies (mAb) and correlated with clinical response.
Major finding: The significantly higher alpha-CGRP levels in patients with CM vs control individuals (P = .004) normalized at 2 weeks (median 40.4 pg/mL; 95% CI 35.6-48.1 pg/mL) and 3 months (median 40.9 pg/mL; 95% CI 36.3-45.9 pg/mL) post-treatment with a CGRP mAb. A significant correlation was observed between decrease in monthly migraine days at the third month and absolute decrease in alpha-CGRP content at the same time-point (P = .02).
Study details: The data come from an observational study including 103 patients with CM who initiated treatment with CGRP mAb and 78 matched control individuals.
Disclosures: This study was supported by the Instituto de Salud Carlos III, IDIVAL Spain, and Lilly grant. J Pascual and V González-Quintanilla declared receiving advisory or speaker honoraria from various sources, including Lilly. Other authors declared no conflicts of interest.
Source: Gárate G et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023 (Apr 11). doi: 10.1002/ana.26658